Janaki Kuruppu

Janaki Kuruppu

Auto-generated profile, based on publicly available information

Janaki Kuruppu

Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2002 in Nature
Verified
Journal Article
Closed access
DDDaniel C. Douek
Daniel C. Douek
JBJason M. Brenchley
Jason M. Brenchley
MBMichael R. Betts
Michael R. Betts
DADavid R. Ambrozak
David R. Ambrozak
BHBrenna J. Hill
Brenna J. Hill
RKRichard A. Koup
Richard A. Koup

1 April 2003 in Blood
Verified
Journal Article
Open access
PDF file
JBJason M. Brenchley
Jason M. Brenchley
NKNitin J. Karandikar
Nitin J. Karandikar
MBMichael R. Betts
Michael R. Betts
DADavid R. Ambrozak
David R. Ambrozak
BHBrenna J. Hill
Brenna J. Hill
RKRichard A. Koup
Richard A. Koup
We present the results of a phase 2 study using thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) in the treatment of 50 patients older than 65 years with newly diagnosed multiple myeloma. Thalidomide 100 mg was administered orally at bedtime continuously, dexamethasone 40 mg was administered orally on days 1 to 4 and 9 to 12, and pegylated liposomal doxorubicin 40 mg/m2 was administered intravenously on day 1 over the 28-day cycle. Response was assessed according to the EBMT criteria. Seventeen (34%) patients achieved CR, 7 (14%) nCR, 5 (10%) VGPR, 15 (30%) PR, and 5 (10%) MR, resulting in an ORR of 98%. Only 1 patient (2%) presented progressive disease. Time to progression (TTP), event-free survival (EFS), and overall survival (OS) projected at 3 years were 60%, 57%, and 74%, respectively, and these parameters were significantly higher in those patients achieving a response of at least VGPR versus those who did not. Grade 3 and 4 nonhematologic adverse events were constipation (10%), fatigue (6%), tremors (4%), mucositis (4%), and palmar-plantar erythrodysesthesia (2%). Grade 3 and 4 neutropenia occurred in 12% of patients. Grade 3 and 4 infections and thromboembolic accidents were observed in 22% and 14% of patients, respectively. In the treatment of elderly patients with newly diagnosed multiple myeloma, ThaDD is a very effective regimen with manageable toxicity.

1 February 2004 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
JBJason M. Brenchley
Jason M. Brenchley
BHBrenna J. Hill
Brenna J. Hill
DADavid R. Ambrozak
David R. Ambrozak
DPDavid A. Price
David A. Price
FGFrancisco J. Guenaga
Francisco J. Guenaga
RKRichard A. Koup
Richard A. Koup
Identification of T-cell subsets that are infected in vivo is essential to understanding the pathogenesis of human immunodeficiency virus (HIV) disease; however, this goal has been beset with technical challenges. Here, we used polychromatic flow cytometry to sort multiple T-cell subsets to 99.8% purity, followed by quantitative PCR to quantify HIVgagDNA directly ex vivo. We show that resting memory CD4+T cells are the predominantly infected cells but that terminally differentiated memory CD4+T cells contain 10-fold fewer copies of HIV DNA. Memory CD8+T cells can also be infected upon upregulation of CD4; however, this is infrequent and HIV-specific CD8+T cells are not infected preferentially. Naïve CD4+T-cell infection is rare and principally confined to those peripheral T cells that have proliferated. Furthermore, the virus is essentially absent from naïve CD8+T cells, suggesting that the thymus is not a major source of HIV-infected T cells in the periphery. These data illuminate the underlying mechanisms that distort T-cell homeostasis in HIV infection.

15 October 2003 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
KLKarin Loré
Karin Loré
MBMichael R. Betts
Michael R. Betts
JBJason M. Brenchley
Jason M. Brenchley
JKJanaki Kuruppu
Janaki Kuruppu
SKSoorena Khojasteh
Soorena Khojasteh
RKRichard A Koup
Richard A Koup
Optimal Ag targeting and activation of APCs, especially dendritic cells (DCs), are important in vaccine development. In this study, we report the effects of different Toll-like receptor (TLR)-binding compounds to enhance immune responses induced by human APCs, including CD123+ plasmacytoid DCs (PDCs), CD11c+ myeloid DCs (MDCs), monocytes, and B cells. PDCs, which express TLR7 and TLR9, responded to imidazoquinolines (imiquimod and R-848) and to CpG oligodeoxynucleotides stimulation, resulting in enhancement in expression of costimulatory molecules and induction of IFN-α and IL-12p70. In contrast, MDCs, which express TLR3, TLR4, and TLR7, responded to poly(I:C), LPS, and imidazoquinolines with phenotypic maturation and high production of IL-12 p70 without producing detectable IFN-α. Optimally TLR ligand-stimulated PDCs or MDCs exposed to CMV or HIV-1 Ags enhanced autologous CMV- and HIV-1-specific memory T cell responses as measured by effector cytokine production compared with TLR ligand-activated monocytes and B cells or unstimulated PDCs and MDCs. Together, these data show that targeting specific DC subsets using TLR ligands can enhance their ability to activate virus-specific T cells, providing information for the rational design of TLR ligands as adjuvants for vaccines or immune modulating therapy.

12 August 2002 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
JKJanaki C. Kuruppu
Janaki C. Kuruppu
MCMary Corretti
Mary Corretti
PMPhilip Mackowiak
Philip Mackowiak
MRMary-Claire Roghmann
Mary-Claire Roghmann
INFECTIVE ENDOCARDITIS (IE) is a disease with high mortality, which requires early diagnosis to give appropriate treatment. Early identification of patients at risk for IE continues to present a challenge because clinical findings can vary widely.1 To aid diagnosis, formal criteria were published by Pelletier and Petersdorf2 in 1977. In 1981, Von Reyn et al3 modified these criteria and proposed strict case definitions, generating 4 categories: definite (based on pathological findings), probable, possible, and rejected (see Appendix 1 of Von Reyn et al3). During the 1980s, transthoracic echocardiography (TTE) became widely used in the evaluation of valvular abnormalities, and the technology has since gained sensitivity for identifying vegetations and valvular regurgitation. In 1994, Durack et al4 proposed the addition of TTE findings to the diagnostic criteria of endocarditis (referred to as the Duke criteria) (see Appendixes 2 and 3 of Durack et al4). In the ensuing years, several groups have confirmed the increased sensitivity of the Duke criteria as compared with the older Von Reyn criteria. Most of these later studies have been retrospective, and have used pathological specimens or autopsy results to define the positive cases.5-15

1 January 2009 in Clinical Medicine. Therapeutics
Verified
Journal Article
Open access
OLOlga Latinovic
Olga Latinovic
JKJanaki Kuruppu
Janaki Kuruppu
CDCharles Davis
Charles Davis
NLNhut Le
Nhut Le
AHAlonso Heredia
Alonso Heredia
Sustained inhibition of HIV-1, the goal of antiretroviral therapy, is often impeded by the emergence of viral drug resistance. For patients infected with HIV-1 resistant to conventional drugs from the viral reverse transcriptase and protease inhibitor classes, the recently approved entry and integration inhibitors effectively suppress HIV-1 and offer additional therapeutic options. Entry inhibitors are particularly attractive because, unlike conventional antiretrovirals, they target HIV-1 extracellularly, thereby sparing cells from both viral- and drug-induced toxicities. The fusion inhibitor enfuvirtide and the CCR5 antagonist maraviroc are the first entry inhibitors licensed for patients with drug-resistant HIV-1, with maraviroc restricted to those infected with CCR5-tropic HIV-1 (R5 HIV-1) only. Vicriviroc (another CCR5 antagonist) is in Phase III clinical trials, whereas the CCR5 antibodies PRO 140 and HGS 004 are in early stages of clinical development. Potent antiviral synergy between maraviroc and CCR5 antibodies, coupled with distinct patterns of resistance, suggest their combinations might be particularly effective in patients. In addition, given that oral administration of maraviroc achieves high drug levels in cervicovaginal fluid, combinations of maraviroc and other CCR5 inhibitors could be effective in preventing HIV-1 transmission. Moreover, since CCR5 antagonists prevent rejection of transplanted organs, maraviroc could both suppress HIV-1 and prolong organ survival for the growing number of HIV-1 patients with kidney or liver failure necessitating organ transplantation. Thus, maraviroc offers an important treatment option for patients with drug-resistant R5 HIV-1, who presently account for >50% of drug-resistance cases.